Evidence map›Paper›PMID 35911762›Full record

ArticleFrontiers in immunology2022

Host KIR/HLA-C Genotypes Determine HIV-Mediated Changes of the NK Cell Repertoire and Are Associated With Vpu Sequence Variations Impacting Downmodulation of HLA-C.

Sarah Vollmers, Annabelle Lobermeyer, Annika Niehrs, Pia Fittje, Daniela Indenbirken, Jacqueline Nakel, Sanamjeet Virdi, Sebastien Brias, Timo Trenkner, Gabriel Sauer and 19 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. HIV controllers: hope for a functional cure.Frontiers in immunology · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Frontiers in immunology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 16 institutions in 3 countries.

Sarah VollmersLeibniz Institute of Virology, Hamburg, Germany.
Annabelle LobermeyerLeibniz Institute of Virology, Hamburg, Germany.
Annika NiehrsLeibniz Institute of Virology, Hamburg, Germany.
Pia FittjeLeibniz Institute of Virology, Hamburg, Germany.
Daniela IndenbirkenLeibniz Institute of Virology, Hamburg, Germany.
Jacqueline NakelLeibniz Institute of Virology, Hamburg, Germany.
Sanamjeet VirdiLeibniz Institute of Virology, Hamburg, Germany.
Sebastien BriasLeibniz Institute of Virology, Hamburg, Germany.
Timo TrenknerLeibniz Institute of Virology, Hamburg, Germany.
Gabriel SauerDepartment I for Internal Medicine, University Hospital of Cologne, Cologne, Germany.
Sven PeineInstitute for Transfusion Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Georg M N BehrensDepartment for Rheumatology and Clinical Immunology, Hannover Medical School, Hannover, Germany.
Clara LehmannDepartment I for Internal Medicine, Division of Infectious Diseases, University Hospital Cologne, Cologne, Germany.
Anja MeurerCenter for Internal Medicine and Infectiology, Munich, Germany.
Ramona PauliMedizinisches Versorgungszentrum (MVZ) am Isartor, Munich, Germany.
Nils PostelPrinzmed, Practice for Infectious Diseases, Munich, Germany.
Julia RoiderDepartment of Internal Medicine IV, Department of Infectious Diseases, Ludwig-Maximilians University Munich, Munich, Germany.
Stefan ScholtenPraxis Hohenstaufenring, Cologne, Germany.
Christoph D SpinnerGerman Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany.
Christoph StephanInfectious Diseases Unit, Goethe-University Hospital Frankfurt, Frankfurt, Germany.
Eva WolfMUC Research, Munich, Germany.
Christoph WyenDepartment I for Internal Medicine, Division of Infectious Diseases, University Hospital Cologne, Cologne, Germany.
Laura RichertUniversity of Bordeaux, Inserm U1219 Bordeaux Population Health, Inria Sistm, Bordeaux, France.
Paul J NormanDivision of Biomedical Informatics and Personalized Medicine, University of Colorado, Aurora, CO, United States.
Jürgen SauterDKMS, Tübingen, Germany.
Alexander H SchmidtDKMS, Tübingen, Germany.
Angelique HoelzemerLeibniz Institute of Virology, Hamburg, Germany.
Marcus AltfeldLeibniz Institute of Virology, Hamburg, Germany.
Christian KörnerLeibniz Institute of Virology, Hamburg, Germany.
Leibniz Association · DELeibniz Institute of Virology (LIV) · DEGerman Center for Infection Research · DEUniversität Hamburg · DEDeutsche Knochenmarkspenderdatei · DEFriedrich-Ebert-Stiftung e.V. · DEInserm · FRKlinikum rechts der Isar · DEMedizinische Hochschule Hannover · DEMedizinisches Versorgungszentrum Prof. Mathey, Prof. Schofer · DEMUC Research (Germany) · DENational Center for Infectious Diseases · USOrthopädische Praxis · DEUniversity Hospital Cologne · DEUniversity Hospital Frankfurt · DEUniversity of Colorado Anschutz Medical Campus · US

Funding

Natural Killer cells and the Immunogenetics of COVID-19R01AI158410 · NIAID · UNIVERSITY OF COLORADO DENVER · PI NORMAN, PAUL JOHN · 2021 to 2024
$2.9M
NIAID NIH HHS R01 AI158410
6 · The paper itself

Abstract

NK cells play a pivotal role in viral immunity, utilizing a large array of activating and inhibitory receptors to identify and eliminate virus-infected cells. Killer-cell immunoglobulin-like receptors (KIRs) represent a highly polymorphic receptor family, regulating NK cell activity and determining the ability to recognize target cells. Human leukocyte antigen (HLA) class I molecules serve as the primary ligand for KIRs. Herein, HLA-C stands out as being the dominant ligand for the majority of KIRs. Accumulating evidence indicated that interactions between HLA-C and its inhibitory KIR2DL receptors (KIR2DL1/L2/L3) can drive HIV-1-mediated immune evasion and thus may contribute to the intrinsic control of HIV-1 infection. Of particular interest in this context is the recent observation that HIV-1 is able to adapt to host

Indexed as

HIV-1HIV InfectionsGenotypeHistocompatibility Antigens Class IHLA-C AntigensHuman Immunodeficiency Virus ProteinsHumansKiller Cells, NaturalLigandsReceptors, KIRReceptors, Natural Killer CellViral Regulatory and Accessory ProteinsViroporin ProteinsHistocompatibility Antigens Class IHLA-C AntigensHuman Immunodeficiency Virus ProteinsLigandsReceptors, KIRReceptors, Natural Killer CellViral Regulatory and Accessory ProteinsViroporin Proteinsvpu protein, Human immunodeficiency virus 1HIV-1HLA-CKIRNK cellVpu

Identifiers

PMID35911762
PMCPMC9334850
OpenAlexW4285592526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.